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Background: Recently we have isolated and cultured dental pulp stem cell (DPSC) derived from impacted third molar 
(DPSC-M3). The DPSC-M3 was suggested as mesenchymal stem cell, however the cell surface markers were not completely 
clarified. Therefore current study was conducted to investigate the markers. 
Materials and Methods: Passage 5 DPSC-M3 was cultured, labeled and examined with flow cytometer. All markers were 
investigated according to the proposed cell surface marker panel for the minimal identification of human mesenchymal 
stem cell (MSC) by International Society for Cellular Therapy (ISCT). The positive markers were cluster of differentiation 
(CD)90, CD73, CD105, while the negative markers were CD34, CD45, CD11b, CD19, and Human Leukocyte Antigen (HLA)-DR. 
Results: Results showed that the size and granularity of DPSC-M3 were ranged from 75 to 230 and 27 to 203, respectively. 
The cell surface antigens examination showed that CD90, CD105 and CD73 were highly expressed (>95%), meanwhile 
expressions of CD45, CD34, CD11b, CD19 and HLA-DR were <2%. 
Conclusion: Since the all markers expression were in accordance to the proposed cell surface marker panel for the minimal 
identification of human MSC by ISCT, DPSC-M3 could be suggested as  an MSC. 
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Introduction
Stem cells are believed to be a potential alternative to 
repair tissue damage in the concept of regeneration.1-3 The 
role of stem cell became significant after the discovery of 
mesenchymal stem cell (MSC).3,4 MSC has a high capacity 
of proliferation5, differentiation, and regeneration6,7. In 
addition, MSC has useful characteristics in cellular therapy 
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such as hypo-immunogenic and ability to avoid the allogenic 
rejection.8  MSC population can be found in body organs 
and tissues such as adipose tissue9, umbilical cord blood10, 
bone marrow11,  and dental tissue12. Dental stem cells can 
be obtained easily and has showed its capacity to heal and 
regenerate dental tissues.4,13
 Previous studies have reported on isolated human 
dental stem cells, and among the stem cells, dental pulp 
stem cell (DPSC) is commonly used in stem cells research.14 
DPSC showed differentiation potency in which it can 
differentiate into adipocyte, odontoblast, chondrocyte, 
myoblast, and neurogenic cells.15,16 Some cell surface 
antigens of DPSC detected by immunohistochemistry are 
cluster of differentiation (CD)73, CD90, CD49, CD51, 
CD61, CD166/ALCAM, CD105, CD146, CD106, CD44, 
CD9, CD10 CD13, CD59, and CD271.17-19 In order for 
scientists to be able to identify the MSC and compare their 
studies,  International Society for Cellular Therapy (ISCT) 
has proposed  three  specific  criteria  to  define  MSC. 
Among the criteria, there are positive (CD73, CD90, and 
CD105) and negative (CD45, CD34, CD11b, CD19 and 
Human Leukocyte Antigen (HLA)-DR) expressions of 
specific surface antigens, detected using flow cytometry.20 
 Recently, DPSC was isolated from impacted third 
molar (DPSC-M3).21 The DPSC-M3 was reported to 
express CD117, one of the stem cell marker, and to have an 
osteogenic potential. The DPSC-M3 were plastic adherent 
as well, suggesting that the DPSC-M3 might be having the 
MSC property. Therefore current study was conducted to 
investigate the cell surface marker of DPSC-M3 according 
to ISCT criteria.
Materials and methods
DPSC-M3 thawing and cultures
Previously reported cryopreserved passage 5 DPSC-M3 
was thawed and cultured in Dulbecco’s modified Eagle’s 
medium (Gibco, Grand Island, NY, USA) supplemented 
with fetal bovine serum (Gibco) and amphotericin, 
penicillin, streptomycin (Gibco).21 Cultured DPSC-M3 was 
then subjected into flow cytometric analysis.
Flow cytometric analysis
Flow cytometric analysis was performed using BD 
Stemflow hMSC Analysis Kit (BD Biosciences, Franklin 
Lakes, NJ, USA). The panel in this kit was made according 
to the proposed cell surface marker panel for the minimal 
identification of human MSC by ISCT.20 Briefly, 1x107 
DPSC-M3 were labeled with/without antibodies and their 
isotypes for positive markers of CD90, CD73, CD105, 
and negative markers of CD34, CD45, CD11b, CD19, 
and HLA-DR. For positive markers, the antibodies were 
fluorescein isothiocyanate (FITC)-conjugated mouse anti-
human CD90 (Clone: 5E10), peridinin chlorophyll protein 
(PerCP)-cyanine (Cy)5.5-conjugated mouse anti-human 
CD105 (Clone: 266) and Alkaline Phosphatase Conjugate 
(APC)-conjugated mouse anti-human CD73 (Clone: AD2). 
The positive isotype antibodies were FITC-conjugated 
mouse anti-human IgG1 κ (Clone: X40), PerCP- Cy5.5-
conjugated mouse anti-human IgG1 κ (Clone: X40) and 
APC-conjugated mouse anti-human IgG1 κ (Clone: X40). 
Meanwhile for negative markers, all antibodies were 
conjugated with phycoerythrin (PE) (PE-conjugated CD45 
(Clone: HI30), PE-conjugated CD34 (Clone: 581), PE-
conjugated CD11b (Clone: ICRF44), PE-conjugated CD19 
(Clone: HIB19) and PE-conjugated HLA-DR antibodies 
(Clone: G46-6). The negative isotype antibodies were PE-
conjugated mouse anti-human IgG1 κ (Clone: X40), PE-
conjugated mouse anti-human IgG2a κ and PE-conjugated 
mouse anti-human IgG2b κ  (Clone: G155-178). Individual 
positive controls are included for compensation set-up in 
the kit. The labeled-cells were then loaded into FACSCanto 
II (BD) and analyzed with FACSDiva software (BD). 
Results
Size and granularity of DPSC-M3
The FSC for size and the SSC for granularity of DPSC-M3 
are shown in dot plot (Figure 1). The size and granularity 
of DPSC-M3 were ranged from 75 to 230 and 27 to 203, 
respectively. 
Figure 1. The size and granularity of DPSC-M3. DPSC-M3 in 
passage 5 was harvested and analyzed using FACSCanto for FSC 
and SSC. FSC and SSC of DPSC-M3 were examined three times. 
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DPSC-M3 surface marker expression 
The dot plot results of unlabeled and isotype antibodies-
labeled DPSC-M3 for negative markers and CD90, showed 
that the cells were located in Q3 areas (Figure 2A1a and 
2A1b)  with the percentage ranging from 98.6 to 99% for 
unlabeled DPSC-M3 and from 87.8 to 98% for isotype 
antibodies-labeled DPSC-M3 (Table 1). The dot plot results 
of antibodies-labeled  DPSC-M3 showed that the cells were 
located in Q4 areas (Figure 2A1c) with the percentage 
ranging from 99.1-99.6% (Table 1). 
 The histogram results of unlabeled, isotype antibodies-
labeled and antibodies-labeled DPSC-M3 for negative 
markers are shown in Figure 2A2a, 2A2b and 2A2c, 
respectively. The percentages of histogram results for the 
negative markers, located in P3 areas, were ranging from 
0 to 0.1% for unlabeled DPSC-M3, from 0.1 to 0.3% for 
isotype antibodies-labeled DPSC-M3 and from 0 to 0.1% 
for antibodies-labeled DPSC-M3 (Table 1). Meanwhile, 
the histogram  results  of  unlabeled,  isotype  antibodies-
labeled and  antibodies-labeled  DPSC-M3  for  CD90  are 
shown  in Figure 2A3a, 2A3b, and 2A3c, respectively. 
The percentages of histogram results for CD90, located 
in P2 areas, were ranging from 0.3 to 0.5% for unlabeled 
DPSC-M3, from 0.4 to 0.6% for isotype antibodies-labeled 
DPSC-M3 and from 97 to 97.2% for antibodies-labeled 
DPSC-M3 (Table 1). 
 The dot plot results of unlabeled and isotype 
antibodies-labeled DPSC-M3 for CD73 and CD105, 
showed that the cells were located in Q3-1 areas (Figure 
2B1a and 2B1b)  with the percentage ranging from 99.4 to 
99.7% for unlabeled DPSC-M3 and from 98.1 to 99% for 
isotype antibodies-labeled DPSC-M3 (Table 2). The dot 
plot results of antibodies-labeled  DPSC-M3 showed that 
the cells were located in Q2-1 areas (Figure 2B1c) with the 
percentage ranging from 99.7 to 100% (Table 2). 
 The histogram results of unlabeled, isotype antibodies-
labeled and antibodies-labeled DPSC-M3 for CD73 are 
shown in Figure 2B2a, 2B2b and 2B2c, respectively. The 
percentages of histogram results for the CD73, located in 
P5 areas, were 0 for unlabeled DPSC-M3, ranging from 
0.1 to 0.4% for isotype antibodies-labeled DPSC-M3 and 
from 98.7 to 99.2% for antibodies-labeled DPSC-M3 (Table 
2). Meanwhile, the histogram results of unlabeled, isotype 
antibodies-labeled and antibodies-labeled DPSC-M3 
for CD105 are shown in Figure 2B3a, 2B3b, and 2B3c, 
respectively. The percentages of histogram results for 
CD105, located in P4 areas, were ranging from 0.4 to 0.8% 
for unlabeled DPSC-M3, from 1.6 to 1.9% for isotype 
antibodies-labeled DPSC-M3 and from 97 to 98.8% for 
antibodies-labeled DPSC-M3 (Table 2).
Discussion
The results showed that sizes of DPSC-M3 were from 70 
to 230, while the granularity of DPSC-M3 were from 30 
to 220. The size and granularity of DPSC-M3 are slightly 
different when compared with other MSCs obtained from 
various tissues, like bone marrow and wharton’s jelly (WJ-
MSC).22,23 Several researches stated that cells with smaller 
size have higher proliferation ability, expressed more MSC 
marker, and expressed less senescence-associated marker 
expression.22,23 Compared with DPSC-M3, the size and 
granularity of WJ-MSC are smaller, suggesting that WJ-
MSC is more pluripotent than DPSC-M3.
 Current results of cell surface antigens examination 
showed  that  CD90,  CD105  and  CD73  were  highly 
expressed (>95%), meanwhile expressions of CD45, 
CD34, CD11b, CD19 and HLA-DR were <2%. These 
results suggest that the examined DPSC-M3 is an MSC. 
Previously, dental pulp of third molars had been been 
reported.24  It was termed as human tooth germ stem cells 
(hTGSCs) and characterized positive for CD73, CD90, 
CD105 and CD166, but negative for CD34, CD45 and 
CD133.24  The hTGSCs  were  suggested  as  mesenchymal-
like  stem  cells. The markers were almost the same with 
slight differences for CD166, CD133, CD11b, CD19 and 
HLA-DR. Both DPSC-M3  and hTGSCs were cultured in 
the same condition, suggesting that both DPSC-M3 and 
hTGSCs were similar.
 There are some potential usages of DPSC-M3, one 
of them  is  the  regenerative  treatment  in  dentistry.13 
Besides that, stem cell exosomes could be useful to induce 
surrounding normal cell growth25 and to inhibit tumor cell 
growth10. For tissue regenerative treatment purposes, high 
number of stem cell is necessary.26 Since number of isolated 
DPSC-M3 was low, DPSC-M3 should be propagated to 
reach optimal cell number. Several approaches have been 
reported showing that stem cell proliferation could be 
induced with supplements/growth factors27-29 and herbal 
extracts30-32.  Hence, this study should be explored to 
enhance the development in DPSC.
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Unlabeled Isotype Antibody
Figure 2. Dot plot and histogram results of DPSC-M3. DPSC-M3 in passage 5 was harvested and labeled with antibodies for negative 
markers (CD45, CD34, CD11b, CD19 and HLA-DR) and CD90 isotype antibody (A1b) or CD90 antibody (A1c). DPSC-M3 was also 
labeled with CD73 and CD105 isotype antibodies (B1b) or with CD73 and CD105 antibodies (B1c). The examination was conducted 
three times. A1a and B1a: unlabeled DPSC. A2a-c: histograms for negative markers of A1a-c, respectively. A3a-c: histograms for CD90 
of A1a-c, respectively. B2a-c: histograms for CD73 of B1a-c, respectively. B3a-c: histograms for CD105 of B1a-c, respectively. Neg: 
negative markers.
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Q1 Q2 Q3 Q4 P2 P3
Unlabeled 1 0 0.2 98.6 1.2 0.4 0.1
(A1a, A2a and A3a) 2 0 0 99.0 1.0 0.3 0
3 0 0.1 98.8 1.1 0.5 0
Isotype Antibodies-labeled 1 1 0.9 97.3 0.8 0.5 0.2
(A1b, A2b and A3b) 2 0.7 0.7 98.0 0.6 0.4 0.1
3 0.5 1.0 87.8 0.7 0.6 0.3
Antibodies-labeled 1 0 0.3 0.5 99.2 97 0.1
(A1c, A2c and A3c) 2 0 0.5 0.4 99.1 97.2 0
3 0 0.1 0.3 99.6 97 0
Group Unit
Gated Areas (%)
Table 1. The percentage of negative markers and CD90. Group and gated areas were correlated 
with dot plot and histogram results of Figure 2. The examination was conducted three times.
Q1-1 Q2-1 Q3-1 Q4-1 P4 P5
Unlabeled 1 0.1 0 99.5 0.4 0.6 0
(B1a, B2a and B3a) 2 0 0 99.7 0.3 0.4 0
3 0 0 99.4 0.6 0.8 0
Isotype Antibodies-labeled 1 0.3 0.3 98.5 0.9 1.7 0.3
(B1b, B2b and B3b) 2 0.2 0.2 99.0 0.6 1.6 0.1
3 0.4 0.5 98.1 1.0 1.9 0.4
Antibodies-labeled 1 0.1 99.9 0 0 98.8 99.0
(B1c, B2c and B3c) 2 0 100.0 0 0 97.6 99.2
3 0.3 99.7 0 0 97.0 98.7
Group Unit
Gated Areas (%)
Table 2. The percentage of CD73 and CD105. Group and gated areas were correlated with dot plot 
and histogram results of Figure 2.The examination was conducted three times.
Conclusion
Since CD73, CD90 and CD105 were positively expressed, 
meanwhile CD34, CD45, CD11b, CD19 and HLA-DR 
were negatively expressed, therefore DPSC-M3 could be 
suggested as  an MSC. 
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